By Fineline Cube 
UK-based pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK) has announced a favorable vote from the US Advisory Committee on Immunization Practices (ACIP) for its respiratory syncytial virus (RSV) vaccine Arexvy. The recommendation supports the use of Arexvy in adults aged 50-59 who are at increased risk for severe RSV disease.
ACIP Recommendation Basis
The ACIP’s recommendation was based on positive results from a Phase III trial (NCT05590403) evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59. This includes individuals with underlying medical conditions that increase their risk of RSV-associated lower respiratory tract disease (RSV-LRTD), similar to older adults aged 60 and above where vaccine efficacy has already been demonstrated.
Arexvy Approval and Availability
Arexvy has received approval in 61 countries, including Europe, Japan, and the US, for the prevention of RSV-LRTD in individuals aged 60 and older. Additionally, it is approved in the US, EU/EEA countries, and Japan for use in individuals aged 50-59 who are at increased risk for RSV-related lower respiratory disease due to certain underlying medical conditions.